UBS Group
BOLT icon

UBS Group’s Bolt Biotherapeutics BOLT Stock Holding History

UBS Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7 Sell
2
-253
-99% -$966 ﹤0.01% 11090
2026
Q2 		$982 Sell
255
-532
-68% -$2.5K ﹤0.01% 9675
2026
Q1 		$3.18K Buy
787
+272
+53% +$1.42K ﹤0.01% 9128
2025
Q4 		$2.82K Buy
515
+512
+17,067% +$2.75K ﹤0.01% 9216
2025
Q3 		$16 Sell
3
-180
-98% -$998 ﹤0.01% 10157
2025
Q2 		$1.06K Sell
183
-5,392
-97% -$35.7K ﹤0.01% 9678
2025
Q1 		$44.6K Buy
5,575
+2,269
+69% +$21.8K ﹤0.01% 7677
2024
Q4 		$35.4K Buy
3,306
+1,541
+87% +$18.6K ﹤0.01% 7509
2024
Q3 		$22.9K Sell
1,765
-676
-28% -$9.32K ﹤0.01% 7289
2024
Q2 		$36.6K Buy
2,441
+1,832
+301% +$36.1K ﹤0.01% 6927
2024
Q1 		$17K Buy
609
+226
+59% +$5.23K ﹤0.01% 6993
2023
Q4 		$8.57K Buy
383
+379
+9,475% +$7.38K ﹤0.01% 7541
2023
Q3 		$89 Buy
+4
New +$98 ﹤0.01% 8911
2022
Q3 		– Sell
-126
Closed -$5K – 10344
2022
Q2 		$5K Buy
126
+47
+59% +$1.82K ﹤0.01% 8846
2022
Q1 		$4K Buy
79
+78
+7,800% +$5.25K ﹤0.01% 9273
2021
Q4 		$0 Sell
1
-12
-92% -$2.28K ﹤0.01% 10263
2021
Q3 		$3K Buy
+13
New +$3.67K ﹤0.01% 8794
2021
Q2 		– Sell
-23
Closed -$15K – 9393
2021
Q1 		$15K Buy
+23
New +$15K ﹤0.01% 7618

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group's BOLT Position: Q3 2026 in Review

UBS Group reduced its Bolt Biotherapeutics (BOLT) stake by 99% in Q3 2026, selling an estimated $966 and leaving 2 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #11090.

UBS Group first reported a position in BOLT in Q1 2021 and has held it in 18 quarters since. The position peaked at $44.6K in Q1 2025. 9 funds tracked by Wall St. Rank hold BOLT as of Q3 2026.

  • UBS Group held 2 shares of Bolt Biotherapeutics worth $7 as of Q3 2026.
  • UBS Group sold 253 Bolt Biotherapeutics shares in Q3 2026, an estimated $966.
  • Bolt Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #11090 holding.
  • UBS Group first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 18 quarters since.
  • UBS Group's Bolt Biotherapeutics position peaked at $44.6K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.